Table 2. Selected clinical studies involving cardiac perfusate solutions.
| Study | Solution | Cases | Patient survival | Graft failure |
|---|---|---|---|---|
| Remadi (15) | CEL | 70 | 91.4% (30 d) | 10% |
| De Santo (16) | CEL | 200 | 88% (1 y) | – |
| Wieselthaler (17) | CEL vs. HTK | 48 (CEL 24, HTK 24) | No diff (CEL 4.2%, HTK 8.3%; P not listed) | No diff (CEL 4.2%, HTK 8.3%) |
| Vega (18) | CEL vs. several | 131 (CEL 64, Cntrl 67) | No diff (30 d) (CEL 94%, Cntrl 88%; P not listed) | No diff (30 d) (CEL 6.3%, Cntrl 13.4%; P not listed) |
| Cannata (19) | CEL vs. HTK vs. Pleg | 133 (CEL 38, HTK 61, Pleg 34) | No diff (in-hosp) (CEL 89.5%, HTK 83.7%, Pleg 85.3%; P=0.717) | No diff (CEL 10.5%, HTK 14.7%, Pleg 14.7%; P=0.814) |
| Kofler (20) | UW vs. HTK | 340 (UW 118, HTK 222) | UW > HTK (UW 80.1%, HTK 66.1%; P<0.001) | – |
| George (21) | UW vs. CEL | 174 (UW 42, CEL 132) | No diff (1 y) (UW 79.5%, CEL 80.3%; P=0.92) | UW > CEL (UW 0.0%, CEL 10.6%; P=0.02) |
| Garlicki (22) | UW vs. CEL vs. HTK | 224 (UW 64, CEL 28, HTK 132) | No diff (90 d) (UW 84%, CEL 86%, HTK 88%; P not listed) | UW 9.4%, CEL 0.0%, HTK 4.5%; P not listed |
| George (23) | UW vs. CEL | 4,910 (UW 3,107, CEL 1,803) | UW > CEL (UW 89.6%, CEL 87%, P<0.01) | – |
Abbreviations: Cntrl, control; no diff, no statistically significant difference; UW, University of Wisconsin; CEL, Celsior; HTK, histidine-tryptophan-ketoglutarate; Pleg, Plegisol; in hosp, in-hospital.